Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	377 people Data from 1 RCT	<50% reduction in Positive and Negative Syndrome Scale (PANSS) positive subscore short term with olanzapine (5–20 mg/day, mean dose 13.1 mg/day) with risperidone (2–6 mg/day, mean dose 4.7 mg/day) Absolute results not reported	RR 1.02 95% CI 0.96 to 1.07		Not significant
Systematic review	661 people 5 RCTs in this analysis	Mean difference in average endpoint PANSS positive subscore short term with olanzapine with risperidone Absolute results not reported	Mean difference +0.48 95% CI –0.57 to +1.53		Not significant
Systematic review	231 people 3 RCTs in this analysis	Mean difference in average endpoint PANSS positive subscore medium term with olanzapine (7.5–40 mg/day) with risperidone (1.5–16 mg/day) Absolute results not reported	Mean difference –1.58 95% CI –3.20 to +0.03		Not significant
Systematic review	810 people 5 RCTs in this analysis	Mean difference in average endpoint PANSS positive subscore long term with olanzapine (2.5–20 mg/day) with risperidone (0.5–12 mg/day) Absolute results not reported	Mean difference –0.68 95% CI –1.40 to +0.04		Not significant
Systematic review	661 people 5 RCTs in this analysis	Mean difference in average endpoint PANSS negative subscore short term with olanzapine with risperidone Absolute results not reported	Mean difference –0.19 95% CI –1.22 to +0.85		Not significant
Systematic review	231 people 3 RCTs in this analysis	Mean difference in average endpoint PANSS negative subscore medium term with olanzapine (7.5–40 mg/day) with risperidone (1.5–16 mg/day) Absolute results not reported	Mean difference 0.00 95% CI –1.59 to +1.58		Not significant
Systematic review	810 people 5 RCTs in this analysis	Mean difference in average endpoint PANSS negative subscore long term with olanzapine (2.5–20 mg/day) with risperidone (0.5–12 mg/day) Absolute results not reported	Mean difference –0.81 95% CI –1.54 to –0.07	Effect size not calculated	olanzapine
Systematic review	308 people Data from 1 RCT	Mean difference in average endpoint Scale for the Assessment of Negative Symptoms (SANS) total subscore long term with olanzapine (10–20 mg/day, mean dose 17.2 mg/day) with risperidone (4–12 mg/day, mean dose 7.2 mg/day) Absolute results not reported	Mean difference –1.40 95% CI –2.43 to –0.37	Effect size not calculated	olanzapine
Systematic review	80 people Data from 1 RCT	<0.5 SD improvement in global neurocognitive score medium term with olanzapine (10–40 mg/day, mean dose 30.4 mg/day) with risperidone (4–16 mg/day, mean dose 11.6 mg/day) Absolute results not reported	RR 0.77 95% CI 0.52 to 1.14		Not significant
Systematic review	52 people Data from 1 RCT	Mean difference in average endpoint global neurocognitive score medium term with olanzapine (10–40 mg/day) with risperidone (4–16 mg/day) Absolute results not reported	Mean difference –0.04 95% CI –0.39 to +0.31		Not significant
Systematic review	163 people Data from 1 RCT	Mean difference in average endpoint neurocognitive composite score long term with olanzapine (5–20 mg/day) with risperidone (2–10 mg/day) Absolute results not reported	Mean difference –0.01 95% CI –0.13 to +0.11		Not significant
Systematic review	612 people 3 RCTs in this analysis	No clinically important response on Clinical Global Impression scale (CGI) score 200/307 (65%) with olanzapine 208/305 (68%) with risperidone	RR 1.07 95% CI 0.90 to 1.27		Not significant
Systematic review	394 people 2 RCTs in this analysis	Mean average CGI score long term with olanzapine with risperidone Absolute results not reported	WMD +0.08 95% CI –0.15 to +0.32		Not significant
Systematic review	339 people Data from 1 RCT	No response 70/172 (41%) with olanzapine 63/167 (38%) with risperidone	RR 0.93 95% CI 0.71 to 1.21		Not significant
Systematic review	339 people Data from 1 RCT	No response 84/172 (49%) with olanzapine 95/167 (57%) with risperidone	RR 1.16 95% CI 0.95 to 1.43		Not significant
Systematic review	339 people Data from 1 RCT	No response 111/172 (65%) with olanzapine 123/167 (74%) with risperidone	RR 1.14 95% CI 0.99 to 1.30		Not significant
Systematic review	339 people Data from 1 RCT	No response 136/172 (79%) with olanzapine 147/167 (88%) with risperidone	RR 1.11 95% CI 1.01 to 1.22	Small effect size	olanzapine
Systematic review	80 people Data from 1 RCT	Mean total PANSS score short term with olanzapine with risperidone Absolute results not reported	WMD +0.70 95% CI –7.01 to +8.41		Not significant
Systematic review	80 people Data from 1 RCT	Mean total PANSS score medium term with olanzapine with risperidone Absolute results not reported	WMD +4.50 95% CI –4.70 to +13.70		Not significant
Systematic review	435 people 3 RCTs in this analysis	Mean total PANSS score long term with olanzapine with risperidone Absolute results not reported	WMD 5.80 95% CI 0.30 to 11.31	Effect size not calculated	olanzapine